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The Mycophenolate Steroids Sparing (MYSS) study found that in renal transplant recipients who were on immunosuppressive
therapywith the cyclosporinemicroemulsionNeoral, mycophenolatemofetil (MMF)was not better than azathioprine in preventing
acute rejection at 21 mo after transplantation andwas 15 timesmore expensive. TheMYSS Follow-up Study, an extension ofMYSS,
was aimed at comparing long-term outcome of 248 MYSS patients according to their original randomization to MMF (1 g twice
daily) or azathioprine (75 to 100 mg/d). Primary outcome was estimated GFR at 5 yr after transplantation. Mean 5-yr GFR difference
between azathioprine and mycophenolate was 4.67 ml/min per 1.73 m2 (95% confidence interval [CI] 0.43 to 9.77 ml/min per 1.73
m2; P  0.07). GFR from month 6 (mean  SEM: 54.3  1.6 versus 53.9  1.5 ml/min per 1.73 m2; P  0.83) to month 72 after
transplantation (49.5  2.2 versus 47.3  2.4 ml/min per 1.73 m2; P  0.50); GFR slopes (mean  SEM: 1.10  0.56 versus 1.23 
0.31 ml/min per 1.73 m2 per year; P 0.83); and 72-mo patient mortality (4.0 versus 4.0% [P 0.95]; HR 0.96; 95% CI 0.28 to 3.31; P
0.95), graft loss (6.8 versus 6.1% [P  0.82]; HR 0.89; 95% CI 0.32 to 2.46; P  0.83), incidence of persistent proteinuria (25.0 versus
27.4%; P  0.72), late (>6 mo after transplantation) rejections (25.3 versus 21.2%; P  0.53), and adverse events were similar on
azathioprine (n  124) and MMF (n  124), respectively. Outcomes in the two groups were comparable also among patients with
or without steroid therapy, considered separately. In kidney transplantation, the long-term risk/benefit profile of MMF and
azathioprine therapy in combination with cyclosporine Neoral is similar. In view of the cost, standard immunosuppression
regimens for kidney transplantation should perhaps include azathioprine rather than MMF.
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Mycophenolate mofetil (MMF), an ester prodrug of my-cophenolic acid, was introduced in clinical practice in1997 as a novel antirejection drug (1). It suppresses
proliferation of T and B lymphocytes by inhibiting inosine mono-
phosphate dehydrogenase, a crucial enzyme in the de novo path-
way of purine synthesis in the S phase of the cell cycle (2). In other
eukaryotic cells, however, inosine monophosphate dehydroge-
nase inhibition has little effect on cell division because purines can
also be generated from nucleotide breakdown products. Because
lymphocytes lack this “salvage pathway,”MMF specifically inhib-
its their proliferation, thereby limiting cell-mediated immunity,
but has little impact on other tissues with high proliferative activ-
ity, such as skin, intestine, and bonemarrow (2). This property has
been presented as a major advantage over other, less selective
antiproliferative agents such as azathioprine (3).
Three groundbreaking, prospective, randomized, double-
blind clinical trials in a total of 1593 patients who received an
immunosuppressive regimen that included cyclosporine Sand-
immune (Novartis, Basel, Switzerland) and steroids (4–6)
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found a significantly lower proportion of patients with a first
rejection episode on MMF 2 g/d (33.2%) or 3 g/d (35.0%) than
on azathioprine or placebo (50.3%). A pooled analysis of the
three trials found that this trend was still consistent at 1 yr (7).
On the basis of these findings, European regulatory agencies
and the US Food and Drug Administration approved MMF for
the prevention of rejection in renal transplantation. In the sub-
sequent years, MMF progressively replaced azathioprine as a
part of standard treatment for preventing rejection in solid
organ and bone marrow transplantation in most centers world-
wide (8).
In 1997, however, at the same time MMF was introduced in
clinical practice, a microemulsion preparation of cyclosporine,
Neoral (Novartis), became available. The microemulsion was
developed to provide greater and more consistent exposure to
cyclosporine than the older, oil-based Sandimmune formula-
tion (9). This facilitated the individual tailoring and monitoring
of cyclosporine therapy, which translated into a reduced inci-
dence of acute rejection episodes and an improved graft sur-
vival, without increasing adverse effects related to cyclosporine
toxicity, not only in kidney transplantation (10,11) but also in
other clinical settings such as heart (12) and liver (13) trans-
plantation. As a result of the better risk/benefit profile, Neoral
soon became the preferred form of cyclosporine in many cen-
ters (9,11,14).
The Mycophenolate Steroids Sparing (MYSS) study pub-
lished in 2004 (15) was designed to test formally whether MMF
retains its better antirejection activity even in immunosuppres-
sive regimens that use the cyclosporine microemulsion formu-
lation Neoral as opposed to Sandimmune. The MYSS trial was
a fully independent, academic study and was not funded by
pharmaceutical companies. It compared the incidence of acute
rejections in 336 patients who were randomly assigned to MMF
or azathioprine in the context of a Neoral-based immunosup-
pressive regimen. Data showed that MMF was not more effec-
tive than azathioprine in preventing acute rejection at 21 mo
after transplantation, had a similar tolerability profile, but was
15 times more expensive. Because of the relatively limited
follow-up, however, this study could not assess the effects of
MMF and azathioprine on the onset and progression of chronic
allograft dysfunction (16), a syndrome of proteinuria and wors-
ening renal function with progressive nephron loss and scar-
ring of the graft (chronic allograft nephropathy). This is a key
issue because, after recipient death, chronic allograft dysfunc-
tion represents the major cause of graft loss in the long term
(17). Moreover, results from registry analyses showed that con-
tinued treatment with MMF versus azathioprine was associated
with a protective effect against renal function deterioration
beyond 1 yr after transplantation (18) and superior graft sur-
vival at 4 yr (19). Despite the limitations of the retrospective
design of these analyses, these data further limited the possi-
bility to use results of the MYSS trial to change the practice of
most transplant centers to regard MMF as a key component of
immunosuppressive drug regimens that are based on cyclo-
sporine microemulsion.
To address this issue, we designed the MYSS Follow-up
study. This was an extension of the MYSS study and prospec-
tively compared long-term outcomes of the two cohorts of
MYSS patients in the setting of a similar immunosuppressive
regimen based on the microemulsion Neoral, according to their
original randomization to MMF or azathioprine. The results of
this MYSS Follow-up study formed the basis of this report.
Materials and Methods
Patients and Study Design
The MYSS study was a multicenter, prospective, randomized, paral-
lel-group trial that compared the incidence of acute rejection in recip-
ients of a first kidney transplant from deceased donors who were
randomly assigned on a 1:1 basis within each center to receive treat-
ment with 1 g of MMF twice daily or azathioprine once daily (100 mg
if body weight 75 kg, 150 mg if 75 kg) in combination with main-
tenance immunosuppressive therapy with the cyclosporine microemul-
sion Neoral and steroids (see Remuzzi et al. [15] for further details).
From October 1997 to May 2001, 336 patients were included. However,
two patients (one per group) did not receive the transplant for technical
reasons. Thus, 334 patients (167 per group) received the study drugs
(Figure 1). The randomization was centralized at the Laboratory of
Biostatistics of the Clinical Research Centre for Rare Diseases of the
Mario Negri Institute for Pharmacologic Research. At completion of the
first 6-mo treatment period (phase A), steroid dosage was progressively
tapered and discontinued in patients with (1) no more than two acute
rejection episodes, (2) no steroid-resistant rejections, and (3) serum
creatinine concentrations of 177 mol/L (Figure 1). When an acute
rejection episode was diagnosed, oral steroid was renewed at the
dosage before the last reduction or at 6 mg every other day if the patient
had already discontinued the medication. Patients were then followed
up to 21 mo after transplantation (phase B).
Fifty-three patients (28 on azathioprine, 25 on MMF) who were
included in the MYSS core trial and referred to the Centers of Genoa,
Antwerp, and Montpellier were not included because of fund restric-
tions that did not allow covering the costs for active patient follow-up
and data monitoring and recording. Of the remaining 281 patients who
were included in the MYSS trial and referred to the Bergamo, Padua,
Brescia, Turin, Varese, Florence, Palermo, and Naples transplant cen-
ters, 248 patients entered the MYSS Follow-up study, whereas 33 did
not. Reasons for exclusion were death (n  2, both on azathioprine),
dialysis (n  2 in each group), and withdrawal of consent (n  27, 11
in the azathioprine, 16 in the MMF group). Donor and baseline char-
acteristics, immunosuppressive therapy, and concomitant medications
of patients who were or were not included in the follow-up study, as
well as of patients who did or did not complete the study, were similar
(data not shown).
Patients were prospectively followed up to October 2004 by visits
every 6 mo (15 d). Clinical and laboratory parameters were recorded
in dedicated forms and were doubly entered. Finally, MYSS and MYSS
Follow-up databases were merged in a unique database that served for
final analyses. All of these activities were coordinated and monitored
by the Clinical Research Centre of the Mario Negri Institute without the
involvement of pharmaceutical industry sponsorship.
All patients provided written informed consent to enter the MYSS
study and a subsequent oral consent to have their follow-up extended
for at least 2 yr. Outcome data were recorded without interfering with
patient routine clinical management and were handled according to
standard regulations for data registration, use, and preservation of
patient anonymity and privacy.
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Outcomes
Primary outcome variable was estimated GFR (eGFR). Secondary
outcome variables were the rate of GFR decline over time (GFR slope),
the incidence of new-onset persistent proteinuria (urinary protein ex-
cretion 0.5 g/24 h in two consecutive visits in patients without
residual proteinuria since transplantation), patient and graft survival,
acute rejections, and adverse events.
BP, serum creatinine concentration, proteinuria and other relevant
laboratory parameters, treatments, and adverse events including acute
rejections were recorded every 6 mo up to study end. The GFR was
estimated on the basis of the Walser equation (men: GFR  7.57 
(serum creatinine  0.0884)1  0.103  age  0.096  weight  6.66;
women: GFR  6.06  (serum creatinine  0.0884)1  0.080  age 
0.080  weight  4.81), the equation that in renal transplantation
generates the GFR estimates that better predict true GFR as measured
by the iohexol plasma clearance (20). Complementary analyses used
GFR data as estimated by the Modification of Diet in Renal Disease
(MDRD) and Nankivell equations (21,22). The GFR slope was estimated
in patients who had at least two GFR measurements from month 6 after
transplantation (taken as baseline) to study end. The diagnosis of acute
rejection episodes was made on the basis of clinical criteria as in the
MYSS study (15). Kidney biopsy samples were taken whenever appro-
priate to confirm the diagnosis and for all steroid-resistant rejection
episodes.
Statistical Analyses
All analyses were performed according to the original randomization
in the MYSS trial. An additional “on treatment” analysis was per-
formed in patients who assumed only the study drug as per protocol.
Analyses first considered the study population as a whole, and then
patients who completed steroid withdrawal while in the MYSS study
separately from those who did not. For avoiding the confounding effect
of different follow-up periods, main outcomes were also described in
three subcohorts of patients who were actively followed for at least 24,
48, and 72 mo, respectively.
Baseline recipient and donor characteristics were compared accord-
ing to treatment groups by means of t test, 2, or Fisher exact test as
appropriate. Kaplan-Meier analysis was used to investigate whether
survival functions differed between treatment groups. The difference
between the survival curves was assessed by log-rank test. Cox pro-
portional hazards models, with adjustment for main demographic and
clinical covariates (site, donor and recipient gender, donor and recipi-
ent age, donor and recipient weight, and donor serum creatinine) were
used to detect the effect of treatment on time-dependent end points.
Proportional hazards assumptions were checked by means of Schoen-
feld residuals. General linear mixed models were used to compare GFR
levels at various time points (e.g., every 6 mo since transplantation,
between regimen treatments). Statistical analyses were accomplished
with SAS software (version 9.1.3; SAS Institute, Cary, NC). The statis-
tical level of significance was P  0.05. All statistical analyses were
performed by two-tailed tests. The study was not initially powered to
detect a difference in graft survival or function between treatment
groups, and the recruitment was finalized to have all MYSS patients on
active follow-up for at least 2 yr in the setting of the MYSS Follow-up
study.
Results
Patients
Main donor and recipient characteristics at time of transplan-
tation were similar in the two treatment groups—except for a
significantly higher percentage of female patients in the aza-
thioprine arm—in the study population as a whole as well as in
the two cohorts of patients who did or did not complete the
steroid withdrawal protocol (Table 1). Cold ischemia time was
similar between the two treatment arms in the study group as
167 entering phase A 167 entering phase A
168 randomized to AZA 168 randomized to MMF
78 not entering phase B
43 not completing steroid
withdrawal entering
f ollow up
89 entering phase B 88 entering phase B
48 not completing steroid
withdrawal entering
f ollow up
81 completing steroid
withdrawal entering
f ollow up
76 completing steroid
withdrawal entering
f ollow up
35 not entering f ollow up
79 not entering phase B
31 not entering f ollow up
8 not entering
f ollow up
12 not entering
f ollow up
1 not transplanted1 not transplanted
Figure 1. Trial profile.
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whole (azathioprine 16.6  7.2 h; MMF 16.0  6.5 h), as well as
in the two subgroups that did (azathioprine 15.6  6.7 h, MMF
15.7  6.1 h) or did not complete (azathioprine 19.2  7.9 h;
MMF 16.7  7.1 h) steroid withdrawal. Patients were followed
for a median (interquartile range) of 65.5 mo (52.7 to 73.6) in the
azathioprine group and of 64.1 mo (53.8 to 73.6) in the MMF
group. The flowchart of the study is shown in Figure 1. At last
follow-up, 18.5% of patients who were randomly assigned to
azathioprine and 8.1% of those who were randomly assigned to
MMF were on reduced dosages of the study drugs compared
with the dosages at 6 mo after transplantation (i.e., before
steroid reduction or withdrawal).
Primary Efficacy Outcome
GFR. All 248 patients had at least one GFR evaluated dur-
ing the follow-up. Throughout the whole study period, eGFR
was similar in the two treatment groups at each 6-mo visit
(Figure 2). Mean GFR difference between azathioprine and
MMF at 60 mo from transplantation was 4.67 ml/min per 1.73
m2 (95% confidence interval [CI] 0.43 to 9.77 ml/min per 1.73
m2; P  0.07; Table 2). At month 72 after randomization, mean
(SE) GFR was 49.5  2.2 ml/min per 1.73 m2 in the azathio-
prine group and 47.3  2.4 ml/min per 1.73 m2 in the MMF
group (P  0.50). eGFR values at various time points after
transplantation were similar in the two treatment groups even
within cohorts of patients with the same follow-up duration
(Figure 3). Consistent results were obtained by “on treatment”
analyses (data not shown). Among patients who completed
steroid withdrawal considered as a whole, the GFR progres-
sively declined over time with a similar trend in both treatment
groups (Figure 4, top). At variance, among patients who did not
complete steroid withdrawal, those who were on azathioprine
had a GFR with a slight progressive increase during the whole
follow-up, whereas those who were on MMF had a slowly
declining GFR (Figure 4, bottom). This different trend resulted
in a numerically higher GFR at 72 mo after randomization in
patients who were on azathioprine (51.2  4.8 ml/min per 1.73
m2) than in those who were on MMF (36.2  4.2 ml/min per
1.73 m2; P  0.07).
Secondary Efficacy Outcomes
Patient and Graft Outcome. The 72-mo patient (azathio-
prine 4.0%; MMF 4.0%; P  0.95) and graft loss (azathioprine
6.8%; MMF 6.1%; P  0.83) were virtually identical in the two
treatment groups (Figure 5). Patient mortality was also similar
in the two cohorts of patients who did (azathioprine 2.5%;
MMF 2.6%; P  0.96) or did not complete (azathioprine 7.0%;
MMF 6.2%; P 0.80) steroid withdrawal considered separately,
as well as graft loss (completing steroid withdrawal: azathio-
prine 3.8%; MMF 2.8%; P  0.71; not completing steroid with-
drawal: azathioprine 11.9%; MMF 11.1%; P  0.94). Cox model
did not show any difference between treatment groups even
when adjusted for demographic and clinical covariates, cold
ischemia time, steroid withdrawal, and azathioprine or MMF
dosage reduction (at last follow up versus month 6 after trans-
plantation; data not shown).
Table 1. Baseline characteristics of recipients and donorsa
Characteristic
Overall Patient Who CompletedSteroid Withdrawal
Patients Who Did Not Complete
Steroid Withdrawal
Azathioprine
(n  124)
MMF
(n  124) P
Azathioprine
(n  81)
MMF
(n  76) P
Azathioprine
(n  43)
MMF
(n  48) P
Recipients
men 73 (58.9%) 91 (73.4%) 0.02 49 (61%) 52 (68%) 0.30 24 (56%) 39 (81%) 0.01
age (yr) 44.7 (11.6) 41.8 (12.3) 0.06 45.3 (11.5) 40.3 (11.9) 0.01 43.5 (11.7) 44.2 (12.6) 0.79
weight (kg) 65.8 (11.4) 69.5 (13.3) 0.06 66.0 (12.2) 68.9 (13.9) 0.26 65.6 (10.2) 70.6 (12.4) 0.09
serum creatinine
(mg/dl)
8.46 (3.24) 8.50 (2.87) 0.93 8.6 (3.3) 8.4 (2.7) 0.81 8.3 (3.2) 8.6 (3.1) 0.66
SBP (mmHg) 136.2 (21.1) 143.2 (23.5) 0.06 138.3 (22.0) 146.2 (20.3) 0.09 133.0 (19.5) 138.5 (27.6) 0.38
DBP (mmHg) 82.6 (12.8) 85.3 (14.6) 0.24 83.1 (13.3) 86.3 (2.7) 0.27 81.8 (12.4) 83.7 (16.9) 0.63
Donors
men 69 (55.7%) 74 (59.7%) 0.52 50 (62%) 47 (62%) 0.99 19 (44%) 27 (56%) 0.25
age (yr) 42.4 (16.0) 42.5 (15.7) 0.95 41.3 (15.7) 40.2 (16.4) 0.68 44.4 (16.5) 46.1 (13.9) 0.61
weight (kg) 69.4 (10.3) 70.3 (11.8) 0.52 70.5 (10.9) 68.9 (12.2) 0.39 67.3 (9.0) 72.6 (11.0) 0.02
HLA A, B, or
DR mismatches
0.58 0.25 0.68
0 5 (4%) 3 (2%) 4 (5%) 1 (1%) 1 (3%) 2 (4%)
1 28 (23%) 38 (31%) 16 (20%) 24 (32%) 12 (30%) 14 (29%)
2 62 (50%) 53 (43%) 45 (55%) 39 (51%) 17 (39%) 14 (29%)
3 23 (18%) 25 (20%) 16 (20%) 12 (16%) 7 (16%) 13 (27%)
missing 6 (5%) 5 (4%) 0 0 6 (14%) 5 (11%)
aData are n (%) or mean (SD). DBP, diastolic BP; MMF, mycophenolate mofetil; SBP, systolic BP.
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GFR Slopes. Data for slope analyses were available for 121
patients who were on azathioprine and 124 who were on MMF.
GFR slopes were similar in the two treatment arms (azathio-
prine1.10 0.56 ml/min per 1.73 m2 per year; MMF1.23
0.31 ml/min per 1.73 m2 per year; P  0.83) in the study group
as a whole, as well as in the subgroups that did (azathioprine
1.73  0.39 ml/min per 1.73 m2 per year; MMF 1.24  0.38
ml/min per 1.73 m2 per year; P  0.36) or did not complete
(azathioprine 0.19  1.49 ml/min per 1.73 m2 per year; MMF
1.23  0.55 ml/min per 1.73 m2 per year; P  0.35) steroid
withdrawal.
Proteinuria. During the whole follow-up period, 31
(25.0%) patients in the azathioprine group and 34 (27.4%) pa-
tients in the MMF group developed persistent clinical protein-
uria (P  0.67). The number of patients who developed persis-
tent proteinuria was similar in the two treatment groups even
among patients who did (azathioprine n  21 [25.9%]; MMF
n  20 [26.3%]) or did not complete (azathioprine n  10
[23.3%]; MMF n  14 [29.2%] steroid withdrawal.
Adverse Events
Sixty-five (52.4%) patients in the azathioprine arm and 57
(46.0%) in the MMF arm experienced at least one acute rejection
episode throughout the whole study period (P 0.31; Figure 6).
The number of patients who had late occurrence of rejection
(6 mo after transplantation) and were on azathioprine (n 20,
25.3%) and on MMF (n  18, 21.2%) was virtually identical as
well (P  0.53). Among patients who completed steroid with-
drawal, the numbers of patients with acute rejections were
similar in the two study groups (azathioprine n  40 [49.4%];
MMF n  31 [40.8%]; P  0.28). The trend was similar in those
who did not complete steroid withdrawal (azathioprine n  25
[58.1%]; MMF n  26 (54.2%); P  0.70).
The total number of infections was similar in the two study
groups, with no significant differences in the incidence of cy-
tomegalovirus reactivations (Table 3). The number of cardio-
vascular events during the whole follow-up period was similar
in the two treatment arms, whereas there was a NS trend to
more neoplasms in those who were on azathioprine (Table 3).
The overall incidence of adverse events was similar in the two
treatment groups and also in the two cohorts of patients who
did or did not complete steroid withdrawal considered sepa-
rately (Table 3).
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Figure 2. Estimated GFR (eGFR) values at various time points from transplantation in the two treatment groups according to the
original patient randomization in the Mycophenolate Steroids Sparing (MYSS) study. Error bars indicate SE. *P  0.05 versus
mycophenolate mofetil (MMF).
Table 2. Mean (95% CI) GFR difference between the
two treatment groups at various time points during the
study perioda
Months
Mean
Difference
in GFRb
95% CI n P
6 0.45 (3.73 to 4.63) 243 0.83
12 0.38 (4.27 to 3.52) 244 0.85
18 0.26 (3.95 to 3.43) 232 0.89
24 1.05 (2.88 to 4.98) 230 0.60
30 1.41 (2.68 to 5.50) 220 0.50
36 1.11 (2.98 to 5.20) 222 0.59
42 1.41 (2.96 to 5.78) 201 0.53
48 0.27 (4.04 to 4.59) 196 0.90
54 1.68 (3.36 to 6.71) 181 0.51
60 4.67 (0.43 to 9.77) 149 0.07
66 2.40 (3.88 to 8.68) 118 0.45
72 2.19 (4.26 to 8.64) 82 0.50
aCI, confidence interval.
bNegative differences favor MMF; positive differences
favor azathioprine.
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Immunosuppressive Therapy and Concomitant Medications
Cyclosporine trough levels throughout the whole study pe-
riod were similar in the two treatment groups in both cohorts of
patients who did or did not complete steroid withdrawal (Fig-
ure 7). The average dosages of azathioprine (ranging from 69 to
94 mg/d) and MMF (1533 to 1804 mg/d) at each time point of
the follow-up were similar between cohorts of patients who did
or did not complete steroid withdrawal. Among patients who
did not complete steroid withdrawal, the average dosages of
steroid (4 to 6 mg/d) were similar in the two treatment groups.
Throughout the study period, the proportions of patients who
received at least once an angiotensin-converting enzyme inhib-
itor (35.5 versus 36.3%), angiotensin II receptor antagonist (2.4
versus 4.0%), statin (38.7 versus 29.8%), or aspirin (43.6 versus
50.0%) therapy in the azathioprine and MMF groups, respec-
tively, were similar.
Discussion
The MYSS Follow-up study was the longest prospective,
randomized clinical trial ever attempted in kidney transplan-
tation to compare formally the effects of various immunosup-
pressive drug regimens on patient and graft outcomes. Post hoc
analyses of previous registration trials of MMF in kidney trans-
plantation extended the observation period to a maximum of 3
yr after randomization. In the MYSS Follow-up study, outcome
data were recorded over a median of 5.5 yr after patient allo-
cation to MMF or azathioprine treatment. Analyses that were
performed according to the original randomization in MYSS or
to the actual treatment assumed on follow-up consistently
showed that MMF was no better than azathioprine in prevent-
ing chronic allograft dysfunction in deceased-donor renal trans-
plant recipients who were on a cyclosporine Neoral-based im-
munosuppressive therapy. eGFR was similar in the two groups
at 60 mo after transplantation—the primary outcome of the
trial—as well as at each study visit. Consistently, GFR slopes;
patient and graft survival; and the incidence of acute allograft
rejections, new-onset proteinuria, and adverse events were sim-
ilar in both groups throughout the whole study period. The
outcome was similar in the two treatment arms even within the
two subgroups that did or did not complete steroid with-
drawal.
MMF and azathioprine were also equally well tolerated.
Altogether, data of the MYSS Follow-up study suggest that
MMF does not have a long-term better risk-benefit profile than
azathioprine, even in the setting of a dual immunosuppressive
regimen that does not include oral steroids. These findings are
in harmony with data from the registration trials that showed a
similar 3-yr mortality and graft loss in patients who were on
azathioprine (23,24) or placebo (25) compared with those who
were on MMF. Of note, however, regardless of treatment ran-
domization, patient or graft loss was remarkably higher in
previous trials (on average, 19.9% at 3 yr) than in our study
(10.4% over 5.5 yr). Worse long-term outcome was also associ-
ated with a higher incidence of acute rejections at 6 mo (on
average, 42.5%) than in our study (34.5%). This was not ex-
plained by differences in the study treatments, because the
daily dosages of azathioprine (100 or 150 mg if body weight 
or75 kg, respectively) and MMF (2 g) were similar. Therefore,
concomitant treatment most likely had a role. All patients who
were included in the registration trials were on long-term ste-
roid therapy, whereas a substantial proportion of patients who
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were included in the MYSS Follow-up study withdrew steroids
starting from month 6 after transplantation. Therefore, despite
the seemingly less intensive concomitant immunosuppressive
regimen, acute rejections were less frequent and long-term
patient and graft survival were higher in the MYSS Follow-up
study than in the registration trials. This may be the conse-
quence of time-dependent factors that resulted in better patient
care in more recent studies. However, another plausible—even
if not exclusive—explanation may be the introduction of the
cyclosporine microemulsion Neoral that was used in all pa-
tients who were included in the MYSS Follow-up study, but
that was not available when the registration trials were per-
formed. Similar confounders may explain why previous retro-
spective registry analyses (18,19) found a worse long-term pa-
tient and graft survival in patients who were on azathioprine,
who in the large majority of cases received a kidney transplant
before 1997 (i.e., before Neoral became available), than in those
who were on MMF and received a graft in the following years
and, therefore, in the large majority of cases were on concom-
itant treatment with Neoral. Consistent with this interpretation
are data from two studies that were not biased by the con-
founding effect of time or concomitant medications: A pooled
analysis of the three pivotal registration trials showing no
differences in 3-yr graft function and survival on MMF as
compared with azathioprine or placebo (26), and a paired kid-
ney analysis showing similar graft function and survival in 476
renal transplant recipients who were on continued MMF or
azathioprine therapy during a mean follow-up of 3.3 yr (27).
Altogether, these data combined with MYSS Follow-up study
findings, challenge the common belief that MMF has a specific
protective effect against the development of chronic allograft
nephropathy (CAN). This possibility was suggested by exper-
imental data that MMF, in addition to inhibiting lymphocyte
proliferation, has an antiproliferative effect on mesangial and
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vascular smooth muscle cells, monocytes, and fibroblasts that
might in theory prevent or limit the underlying scarring pro-
cesses of CAN. Other potentially beneficial effects of MMF
include inhibition of adhesion molecule expression on endothe-
lial cells—which may retard tissue infiltration by inflammatory
cells—increased apoptosis of monocytes, and reduced antibody
production from B cells (reviewed in reference [28]). That these
effects may translate into a clinically relevant benefit in hu-
mans, however, is unproved. Data in support of this possibility
are generated by sequential studies showing improvements in
graft structure and function after replacement of calcineurin
inhibitors with MMF (29,30). These findings, however, may
reflect a spontaneous recovery from the nephrotoxic effects of
previous cyclosporine or tacrolimus treatment, rather than a
specific protective effect of MMF against CAN. Observational
studies showing a lower incidence of chronic interstitial fibrosis
with MMF than with azathioprine therapy were likely affected
by the confounding effect of time, because outcome data were
not analyzed in the setting of a randomized, prospective design
(31). Only one randomized clinical trial prospectively com-
pared the effects of MMF and azathioprine on the incidence of
biopsy-proven CAN (32). On the basis of the analysis of the
Banff score, MMF as compared with azathioprine therapy was
associated with a lower incidence of nephropathy at 1 yr after
transplantation. However, closer examination of the data (33)
revealed that allograft glomerulopathy, mesangial matrix in-
crease, vascular changes, interstitial fibrosis, and tubular atro-
phy, as well as renal function, were similar in the two treatment
groups. These findings did not allow the conclusion that MMF
is superior to azathioprine in preventing CAN (33). Actually, in
the long term, the opposite might be true, as suggested by a
recent observational study of 1511 renal transplant patients that
showed that at 8.5 yr after transplantation, those who were on
MMF had significantly lower GFR than those who were on
azathioprine (34).
Altogether, the MYSS and MYSS Follow-up studies consis-
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tently show that MMF and azathioprine are equally effective in
preventing both acute rejection and CAN (an equivalent of
chronic rejection) in kidney transplantation. Studies suggest
that MMF may be no better than azathioprine also in other
areas of organ transplantation. A randomized clinical trial re-
cently found that MMF and azathioprine were equally effective
in preventing acute rejection and obliterative bronchiolitis (the
pathologic entity that represents “chronic rejection” in pulmo-
nary allografts) in lung transplant recipients who were on
immunosuppressive treatment with cyclosporine Neoral and
corticosteroids (35).
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Table 3. Patients with adverse eventsa
Parameter
Overall Patients Who CompletedSteroid Withdrawal
Patients Who Did Not
Complete Steroid Withdrawal
Azathioprine
(n  124)
MMF
(n  124) P
Azathioprine
(n  81)
MMF
(n  76) P
Azathioprine
(n  43)
MMF
(n  48) P
Cardio/cerebrovascularb 18 (15) 22 (18) 0.49 12 (15) 11 (14) 0.95 6 (14) 11 (23) 0.27
arrhythmic 3 (2) 2 (2) 0.99 2 (2) 0 (0) 0.50 1 (2) 2 (4) 0.99
ischemic 9 (7) 6 (5) 0.42 5 (6) 5 (7) 0.99 4 (9) 1 (2) 0.18
other causes 11 (9) 16 (13) 0.31 8 (10) 7 (9) 0.89 3 (7) 9 (19) 0.13
Infectionsb 89 (72) 79 (64) 0.17 55 (68) 46 (61) 0.34 34 (79) 33 (69) 0.26
CMV 45 (37) 39 (32) 0.42 28 (35) 22 (29) 0.45 17 (40) 17 (35) 0.69
urinary tract infection 39 (32) 43 (35) 0.59 26 (32) 27 (36) 0.65 13 (30) 16 (33) 0.75
other causes 58 (47) 51 (41) 0.37 32 (40) 26 (34) 0.49 26 (60) 25 (52) 0.42
Cancersb 13 (10) 8 (6) 0.25 11 (14) 3 (4) 0.05 2 (5) 5 (10) 0.30
Kaposi 3 (2) 2 (2) 0.99 2 (2) 1 (1) 0.99 1 (2) 1 (2) 0.99
lymphoproliferative 4 (3) 2 (2) 0.68 4 (5) 0 (0) 0.12 0 (0) 2 (4) 0.50
cutaneous 3 (2) 2 (2) 0.99 2 (2) 2 (2) 0.99 1 (2) 0 (0) 0.47
other 4 (3) 3 (2) 0.99 4 (5) 0 (0) 0.12 0 (2) 3 (6) 0.24
aData are n (%). bSome patients have recorded 1 event.
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arose also some concern about the safety profile of MMF com-
pared with azathioprine. A meta-analysis of 6387 renal trans-
plant patients who were included in 20 randomized clinical
trials of MMF versus azathioprine (36) found a significantly
higher incidence of diarrhea, leucopenia, and cytomegalovirus
disease in those who were on MMF. The Transplant European
Survey on Anemia Management (37), a 5-yr survey of 4263
renal transplant recipients, showed significantly lower hemo-
globin in patients who were on any immunosuppressive drug
combination that included MMF, a finding that was at least in
part explained by lower GFR. Recent reports showed also an
increased risk for tuberculosis in renal transplant patients who
received an immunosuppressive regimen that included MMF
rather than azathioprine (38). However, in our study, we found
a NS trend to more neoplasms on azathioprine than on MMF.
Although the study was not powered to assess the impact of
treatment on these outcomes and a random effect could not be
definitely ruled out, these findings are in harmony with results
of previous retrospective analyses that showed a higher inci-
dence of skin and nondermatologic malignancies with azathio-
prine than with MMF therapy (39).
The MYSS Follow-up study has some limitations. Long-term
outcome was remarkably good regardless of treatment ran-
domization, a finding that may reflect the effectiveness of both
immunosuppressive regimens under evaluation but also the
inclusion of relatively low-risk patients, such as relatively
young white patients who were at their first kidney trans-
plant and who seldom had diabetes as a primary cause of
ESRD. Data from registration trials (23–26) and observational
studies (27), however, suggest that azathioprine and MMF
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Figure 7. Cyclosporine trough levels at various time points from transplantation in the two treatment groups in patients who did
(top) or did not complete (bottom) steroid withdrawal. Error bars indicate SE.
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may have a similar long-term risk/benefit profile also in
second transplant recipients and in patients who are at
higher immunologic risk and are on concomitant treatment
with cyclosporine (or tacrolimus) and steroid, regardless of
Thymoglobulin induction therapy. Whether MMF and aza-
thioprine are equally effective also in renal transplant pa-
tients who are on tacrolimus-based immunosuppressive reg-
imens remains to be addressed. Also, a relatively small
number of patients were available for comparative analyses
after 5 yr of follow-up, and, as in previous registration
trials (23–25), the sample size was not estimated a priori on
the basis of an expected effect on long-term efficacy vari-
ables. A confounding effect of a survival bias on GFR anal-
yses was unlikely because patient and kidney survival were
similar in the two treatment groups, and GFR and event
analyses were consistent in showing similar long-term out-
comes on MMF or azathioprine. Moreover, similar GFR out-
comes were observed also when the analyses were per-
formed in subgroups of patients with homogeneous follow-
up. Finally, failure to detect a long-term benefit of MMF over
azathioprine was not explained by a confounding effect of a
reduction in the MMF dosage aimed to limit the risk of
thrombocytopenia or leukopenia after steroid withdrawal.
Indeed, at last follow-up, the proportion of patients who
were on reduced dosages of MMF was consistently less than
the proportion of patients who were on reduced dosages of
azathioprine, and, at multivariate analyses, patient and graft
outcomes were similar in the two treatment groups even
after adjustment for dosage reduction.
Conclusion
Data from our study, consistent with post hoc analyses of
previous registration trials (23–26) and recent observational
studies (27), suggest that the long-term risk/benefit profile of
MMF and azathioprine therapy in kidney transplantation are
similar, even in the setting of a cyclosporine-based immuno-
suppressive regimen that does not include steroids. Because the
costs for standard treatment with MMF remarkably exceed
those of azathioprine (15), standard immunosuppression regi-
mens for kidney transplantation should perhaps include aza-
thioprine rather than MMF.
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